REGENXBIO Inc. $175.5 Million Common Stock Offering
8/14/2018

Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “RGNX.”

Based in Rockville, Maryland, REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s platform is currently being applied in the development of product candidates for a variety of diseases, including four internally developed product candidates and more than 20 product candidates being developed by REGENXBIO’s licensees.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associates Yoojin L. Kim and Amy L. Larsen. The intellectual property and technology team included partner David R. Bauer and associate Tilak Koilvaram. Counsel Marcie A. Goldstein provided FINRA advice. The tax team included counsel Leslie J. Altus and associate Elina Khodorkovsky. The environmental team included counsel Loyti Cheng. All members of the Davis Polk team are based in the New York office.